On Thursday, Citi maintained a Neutral stance on Integer Holdings Corporation (NYSE:ITGR), with a price target of $130.00. The third quarter of 2024 presented a mixed performance for Integer, as it navigated a challenging comparison year and the impending sale of its Electrochem division, expected to conclude by the end of October.
Integer's Q3 2024 medical revenue reported $431.4 million, a 9% increase as reported and a 4% organic growth, which was slightly below the consensus estimate of $436.1 million. Including non-medical revenue, the total revenue of $440.2 million was virtually in line with the anticipated $440.6 million.
The company saw an improvement in operating margins, which expanded to 17.5% from 15.9%, or to 17.5% from 16.3% when excluding non-medical operations. This increase reflects the benefits of exiting the lower-margin non-medical business. Consequently, Integer's earnings per share (EPS) reached $1.43, marking a 12.6% increase and exceeding the consensus estimate of $1.36.
Despite the lower organic growth in Q3 2024, which decelerated from 5.2% quarter-over-quarter and 17.8% year-over-year to 4%, Integer's management reaffirmed their expectations for the company to grow 200 basis points faster than the market in 2025. Citi's analysis indicates that this slowdown likely represents a normalization in the market environment for Integer.
In other recent news, Integer Holdings Corporation has made significant leadership changes, with Payman Khales assuming the role of Chief Operating Officer and Andrew Senn taking over as President, Cardio & Vascular. The company has also sold its Electrochem division to Ultralife Corporation for $50 million, a strategic move believed to align with its growth strategy. This move followed two major facility expansions in Ireland, further bolstering Integer's manufacturing capabilities.
Integer Holdings' recent financial performance has seen a 9% year-over-year increase in sales, reaching $436 million, despite Q2 earnings per share falling short of estimates at $0.88. The company has reiterated its full-year 2024 revenue guidance, projecting between $1,735 million and $1,770 million.
Analysts from Benchmark, KeyBanc, and Truist Securities have all raised their price targets for Integer Holdings, citing expectations of increased Q3 sales and improved earnings per share.
InvestingPro Insights
Integer Holdings Corporation (NYSE:ITGR) has shown resilience in a challenging market environment, as reflected in its recent financial performance and market position. According to InvestingPro data, the company's revenue growth remains solid at 11.71% over the last twelve months as of Q2 2024, with quarterly revenue growth of 9.04% in Q2 2024. This aligns with the 9% revenue increase reported in the article for Q3 2024.
The company's profitability is also noteworthy, with an EBITDA growth of 22.28% over the last twelve months, indicating improved operational efficiency. This is consistent with the expanded operating margins mentioned in the article.
InvestingPro Tips highlight that ITGR is trading at a low P/E ratio relative to near-term earnings growth, with a PEG ratio of 0.91. This suggests that the stock may be undervalued considering its growth prospects. Additionally, the company's stock has shown a high return over the last year, with a one-year price total return of 75.81%, reflecting investor confidence in Integer's performance and strategy.
For readers interested in a deeper analysis, InvestingPro offers 7 additional tips for Integer Holdings Corporation, providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.